bluuebunny/crossref_metadata_2025 huggingface dataset:
Supplementary Fig. 3 from Ingenol Mebutate Signals via PKC/MEK/ERK in Keratinocytes and Induces Interleukin Decoy Receptors IL1R2 and IL13RA2
Authors: Freiberger Sandra N. , Cheng Phil F. , Iotzova-Weiss Guergana , Neu Johannes , Liu Qinxiu , Dziunycz Piotr , Zibert John R. , Dummer Reinhard , Skak Kresten , Levesque Mitchell P. , Hofbauer Günther F.L.
Published: April 2023

Effect of IM on fibroblasts and melanoma cells and effect of TPA on SCC13 cells.
Supplementary Table 4 from A Multicenter Phase I Study of Pazopanib in Combination with Paclitaxel in First-Line Treatment of Patients with Advanced Solid Tumors
Authors: Kendra Kari L. , Plummer Ruth , Salgia Ravi , O'Brien Mary E. R. , Paul Elaine M. , Suttle A. Benjamin , Compton Natalie , Xu Chun-Fang , Ottesen Lone H. , Villalona-Calero Miguel A.
Published: April 2023

Summary of paclitaxel pharmacokinetic parameters
Supplementary Table 3 from A Multicenter Phase I Study of Pazopanib in Combination with Paclitaxel in First-Line Treatment of Patients with Advanced Solid Tumors
Authors: Kendra Kari L. , Plummer Ruth , Salgia Ravi , O'Brien Mary E. R. , Paul Elaine M. , Suttle A. Benjamin , Compton Natalie , Xu Chun-Fang , Ottesen Lone H. , Villalona-Calero Miguel A.
Published: April 2023

Drug exposure for paclitaxel and pazopanib
Supplementary figure S1 from Mechanisms of Overcoming Intrinsic Resistance to Gemcitabine in Pancreatic Ductal Adenocarcinoma through the Redox Modulation
Authors: Ju Huai-Qiang , Gocho Takeshi , Aguilar Mitzi , Wu Min , Zhuang Zhuo-Nan , Fu Jie , Yanaga Katsuhiko , Huang Peng , Chiao Paul J.
Published: April 2023

Supplementary figure S1. Increased cellular ROS levels in PDAC cells treated with gemcitabine.
Supplementary Table 1 and Supplementary Figures 1 through 5 from Mechanisms of Resistance to Cabazitaxel
Authors: Duran George E. , Wang Yan C. , Francisco E. Brian , Rose John C. , Martinez Francisco J. , Coller John , Brassard Diana , Vrignaud Patricia , Sikic Branimir I.
Published: April 2023

The supplementary data include one table and 5 figures. Table S1 presents cabazitaxel cytotoxic activity in the human breast cancer cell line MCF-7, uterine sarcoma cell line MES-SA, and ovarian cancer cell lines ES-2, MES-OV, and OVCAR-3. Figure S1 presents the molecular structure of cabazitaxel and cytotoxicity curves for three taxanes in MCF-7 cells. Figure S2 shows an immunoblot of drug transporter proteins in parental and drug resistant variants of MCF-7. Figure S3 shown rhodamine123 and BODIPY-paclitaxel accumulation by flow cytometry in parental and resistant variants. Figure S4 shows polymerized versus soluble tubulin in parental vs resistant variants. Figure S5 shows expression of apoptotic regulators.
Supplemental Figure 3 from ANG4043, a Novel Brain-Penetrant Peptide–mAb Conjugate, Is Efficacious against HER2-Positive Intracranial Tumors in Mice
Authors: Regina Anthony , Demeule Michel , Tripathy Sasmita , Lord-Dufour Simon , Currie Jean-Christophe , Iddir Mustapha , Annabi Borhane , Castaigne Jean-Paul , Lachowicz Jean E.
Published: April 2023

A. In vitro binding of ANG4043 and Anti-HER2 mAb to the HER2/Fc chimera protein. B, C. Lack of effect of ANG4043 and Anti-HER2 on the proliferation of HER2-negative MCF-7 (B) and U-87 (C) cells using the [3H] thymidine incorporation assay.
Supplemental Figure 1 from ANG4043, a Novel Brain-Penetrant Peptide–mAb Conjugate, Is Efficacious against HER2-Positive Intracranial Tumors in Mice
Authors: Regina Anthony , Demeule Michel , Tripathy Sasmita , Lord-Dufour Simon , Currie Jean-Christophe , Iddir Mustapha , Annabi Borhane , Castaigne Jean-Paul , Lachowicz Jean E.
Published: April 2023

A. Confirmation of HER2-positive expression status of BT-474 and SKBR3 cells and HER2-negative status of MCF-7, U-87 and HBMEC cells by WB analysis using an anti-HER2 mAb. B. Immunodetection of LRP1 by WB using an antibody directed against the 85 kDa subunit of LRP1 in U-87 and HBMEC. LRP1 expression is not detected in BT-474 cells.
Supplementary Figure S4 from MEK Inhibition Overcomes Cisplatin Resistance Conferred by SOS/MAPK Pathway Activation in Squamous Cell Carcinoma
Authors: Kong Li Ren , Chua Kian Ngiap , Sim Wen Jing , Ng Hsien Chun , Bi Chonglei , Ho Jingshan , Nga Min En , Pang Yin Huei , Ong Weijie Richard , Soo Ross Andrew , Huynh Hung , Chng Wee Joo , Thiery Jean-Paul , Goh Boon Cher
Published: April 2023

Silencing of ERK1/2 enhances cisplatin sensitivity and stabilizes Bim in lung squamous cell carcinoma (SCC) cells.
Supplementary Figure S1 from MEK Inhibition Overcomes Cisplatin Resistance Conferred by SOS/MAPK Pathway Activation in Squamous Cell Carcinoma
Authors: Kong Li Ren , Chua Kian Ngiap , Sim Wen Jing , Ng Hsien Chun , Bi Chonglei , Ho Jingshan , Nga Min En , Pang Yin Huei , Ong Weijie Richard , Soo Ross Andrew , Huynh Hung , Chng Wee Joo , Thiery Jean-Paul , Goh Boon Cher
Published: April 2023

Lack of significantly altered genes in lung squamous cell carcinoma (SCC) tumors.
Supplementary Table S1; Supplementary Figures S1-S2 from P7170: A Novel Molecule with Unique Profile of mTORC1/C2 and Activin Receptor-like Kinase 1 Inhibition Leading to Antitumor and Antiangiogenic Activity
Authors: Jalota-Badhwar Archana , Bhatia Dimple R. , Boreddy Srinivas , Joshi Asavari , Venkatraman Magesh , Desai Nikesh , Chaudhari Sarika , Bose Julie , Kolla Lakshmi S. , Deore Vijaykumar , Yewalkar Nilambari , Kumar Sanjay , Sharma Rajiv , Damre Anagha , More Avinash , Sharma Somesh , Agarwal Veena R.
Published: April 2023

Supplementary Table S1; Supplementary Figures S1-S2. Supplementary Table 1. A) IC50 value of P7170 in pan-PI3K. B) Kinase inhibition data (ProQinase) of P7170 at 250 nM and 1. 5 ÃŽÂ¼M.C) Kinase inhibition profile (KINOMEscan; 320 kinases) of P7170. D) IC50 values of selected kinases on treatment with P7170. Supplementary Figure S1. The growth response curves on treatment of P7170 on various patient-derived cancer cell lines. Supplementary Figure S2. P7170 induces autophagy in A2780 (A) and HCT116 (B) cells.
Supplemental Figure 3 from The MDM2 Inhibitor AMG 232 Demonstrates Robust Antitumor Efficacy and Potentiates the Activity of p53-Inducing Cytotoxic Agents
Authors: Canon Jude , Osgood Tao , Olson Steven H. , Saiki Anne Y. , Robertson Rebecca , Yu Dongyin , Eksterowicz John , Ye Qiuping , Jin Lixia , Chen Ada , Zhou Jing , Cordover David , Kaufman Stephen , Kendall Richard , Oliner Jonathan D. , Coxon Angela , Radinsky Robert
Published: April 2023

Supplemental Figure 3. Body weights of mice in xenograft efficacy studies
Supplemental Figure 2 from The MDM2 Inhibitor AMG 232 Demonstrates Robust Antitumor Efficacy and Potentiates the Activity of p53-Inducing Cytotoxic Agents
Authors: Canon Jude , Osgood Tao , Olson Steven H. , Saiki Anne Y. , Robertson Rebecca , Yu Dongyin , Eksterowicz John , Ye Qiuping , Jin Lixia , Chen Ada , Zhou Jing , Cordover David , Kaufman Stephen , Kendall Richard , Oliner Jonathan D. , Coxon Angela , Radinsky Robert
Published: April 2023

Supplemental Figure 2. AMG 232 treatment causes p53 stabilization, and increased p21 and MDM2 proteins in p53 wild-type cells.
Supplemental Figure 4 from Radioprotection of the Brain White Matter by Mn(III) N-Butoxyethylpyridylporphyrin–Based Superoxide Dismutase Mimic MnTnBuOE-2-PyP5+
Authors: Weitzel Douglas H. , Tovmasyan Artak , Ashcraft Kathleen A. , Rajic Zrinka , Weitner Tin , Liu Chunlei , Li Wei , Buckley Anne F. , Prasad Mark R. , Young Kenneth H. , Rodriguiz Ramona M. , Wetsel William C. , Peters Katherine B. , Spasojevic Ivan , Herndon James E. , Batinic-Haberle Ines , Dewhirst Mark W.
Published: April 2023

Supplemental Figure 4: Model of differential actions of MnTnBuOE-2-PyP5+ in causing the apoptosis of tumor during radiotherapy, while suppressing radation injury to surrounding normal tissue. Such effects are due to the differential redox environment of tumor vs normal cell, in particular much lower ability of cancer cell to remove cytotoxic hydrogen peroxide. Consequently, much higher levels of hydrogen peroxide already exist in tumor cell, and are greatly enhanced upon radiation. In normal cells and tissues, porphyrins suppress cycling inflammatory responses that may result from radiation also.
Supplementary Movie 1 from GPR54 Is a Target for Suppression of Metastasis in Endometrial Cancer
Authors: Kang Hyun Sook , Baba Tsukasa , Mandai Masaki , Matsumura Noriomi , Hamanishi Junzo , Kharma Budiman , Kondoh Eiji , Yoshioka Yumiko , Oishi Shinya , Fujii Nobutaka , Murphy Susan K. , Konishi Ikuo
Published: April 2023

Supplementary Movie 1 from GPR54 Is a Target for Suppression of Metastasis in Endometrial Cancer
Data Supplement from Selective Release of a Cyclopamine Glucuronide Prodrug toward Stem-like Cancer Cell Inhibition in Glioblastoma
Authors: Balbous Anaïs , Renoux Brigitte , Cortes Ulrich , Milin Serge , Guilloteau Karline , Legigan Thibaut , Rivet Pierre , Boissonnade Odile , Martin Sébastien , Tripiana Caroline , Wager Michel , Bensadoun René Jean , Papot Sébastien , Karayan-Tapon Lucie
Published: April 2023

Legends of supplementary legends
Supplementary Figure 3 from USP44+ Cancer Stem Cell Subclones Contribute to Breast Cancer Aggressiveness by Promoting Vasculogenic Mimicry
Authors: Liu Tieju , Sun Baocun , Zhao Xiulan , Li Yanlei , Zhao Xueming , Liu Ying , Yao Zhi , Gu Qiang , Dong Xueyi , Shao Bing , Lin Xian , Liu Fang , An Jindan
Published: April 2023

Supplementary Figure 3. USP44 KD inhibited IL-6 and IL-8 expression in breast CSCs.
Data Supplement from Selective Release of a Cyclopamine Glucuronide Prodrug toward Stem-like Cancer Cell Inhibition in Glioblastoma
Authors: Balbous Anaïs , Renoux Brigitte , Cortes Ulrich , Milin Serge , Guilloteau Karline , Legigan Thibaut , Rivet Pierre , Boissonnade Odile , Martin Sébastien , Tripiana Caroline , Wager Michel , Bensadoun René Jean , Papot Sébastien , Karayan-Tapon Lucie
Published: April 2023

Supplementary Figure 3: CGP-2 decreased nestin mRNA expression.
Supplementary Figure 1 from USP44+ Cancer Stem Cell Subclones Contribute to Breast Cancer Aggressiveness by Promoting Vasculogenic Mimicry
Authors: Liu Tieju , Sun Baocun , Zhao Xiulan , Li Yanlei , Zhao Xueming , Liu Ying , Yao Zhi , Gu Qiang , Dong Xueyi , Shao Bing , Lin Xian , Liu Fang , An Jindan
Published: April 2023

Supplementary Figure 1. AURKA overexpression induced centrosome amplification and stemness development in MCF-7 cells.
Supplementary Table S1 from The TMPRSS2–ERG Gene Fusion Blocks XRCC4-Mediated Nonhomologous End-Joining Repair and Radiosensitizes Prostate Cancer Cells to PARP Inhibition
Authors: Chatterjee Payel , Choudhary Gaurav S. , Alswillah Turkeyah , Xiong Xiahui , Heston Warren D. , Magi-Galluzzi Cristina , Zhang Junran , Klein Eric A. , Almasan Alexandru
Published: April 2023

The proportion of cells in the different phases of the cell cycle at 24 and 48 h following IR, administered alone or in combination with PARPi, determined by flow cytometry.
Supplementary Figures 1 through 5 from A Combinatory Strategy for Detection of Live CTCs Using Microfiltration and a New Telomerase-Selective Adenovirus
Authors: Ma Yanchun , Hao Sijie , Wang Shuwen , Zhao Yuanjun , Lim Bora , Lei Ming , Spector David J. , El-Deiry Wafik S. , Zheng Si-yang , Zhu Jiyue
Published: April 2023

Supplementary figure 1: Replication of recombinant adenoviruses in MCF7 breast cancer cells. Supplementary figure 2: Telomerase expression in normal human cells and cancer cell lines. Supplementary figure 3: Labeling mixtures of HCT116 colon cancer cells and WBCs. Supplementary figure 4: Imaging the mixture of HCT116 colon cancer cells and WBCs. Supplementary figure 5: Imaging the mixture of MCF7 breast cancer cells and WBCs.
Supplementary Figure S1 from The TMPRSS2–ERG Gene Fusion Blocks XRCC4-Mediated Nonhomologous End-Joining Repair and Radiosensitizes Prostate Cancer Cells to PARP Inhibition
Authors: Chatterjee Payel , Choudhary Gaurav S. , Alswillah Turkeyah , Xiong Xiahui , Heston Warren D. , Magi-Galluzzi Cristina , Zhang Junran , Klein Eric A. , Almasan Alexandru
Published: April 2023

TMPRSS2/ERG inhibits Ser2056 DNA-PKcs phosphorylation. Confocal immunostaining for phospho-DNA-PKcs Ser2056 at indicated times following IR in PC3 with or without expression of the TMPRSS2-ERG fusion.
Supplementary Figure 5 from Novel Functions for mda-7/IL-24 and IL-24 delE5: Regulation of Differentiation of Acute Myeloid Leukemic Cells
Authors: Yang Bin-Xia , Duan Yong-Juan , Dong Cheng-Ya , Zhang Fang , Gao Wei-Feng , Cui Xue-Ying , Lin Yong-Min , Ma Xiao-Tong
Published: April 2023

Supplementary Figure 5 from Novel Functions for mda-7/IL-24 and IL-24 delE5: Regulation of Differentiation of Acute Myeloid Leukemic Cells
Supplemental Figure 4 from ΔNP63α Transcriptionally Activates Chemokine Receptor 4 (CXCR4) Expression to Regulate Breast Cancer Stem Cell Activity and Chemotaxis
Authors: DeCastro Andrew J. , Cherukuri Pratima , Balboni Amanda , DiRenzo James
Published: April 2023

Supplemental Figure 4: Chromatin Immunoprecipitation Assay in Immortalized Mammary Epithelial Cells (IMEC). A) ChIP assay performed on IMEC cells using anti-p63 (4A4) and IgG isotype antibodies which were then subjected to real-time PCR. Values are mean relative binding activity over isotype control for endogenous Î”NP63Î±. B) Predicted p63 binding sites on the CXCR4 gene promoter regions [base pairs from transcription start site (TSS) denoted]. Bottom: ChIP assay performed on SUM-102 cells infected with an adenovirus encoding Î”NP63Î±. C) ChIP negative control: Ct-values from qRT-PCR using primers for genomic regions within the CXCR4 promoter devoid of putative Î”NP63Î± binding motifs on SUM-102 lysates that were subjected to ChIP using anti-p63 (4A4) and IgG isotype antibodies. No enrichment of p63 was observed at these sites compared to input and IgG isotype control.
Data Supplement from BET Protein Antagonist JQ1 Is Synergistically Lethal with FLT3 Tyrosine Kinase Inhibitor (TKI) and Overcomes Resistance to FLT3-TKI in AML Cells Expressing FLT-ITD
Authors: Fiskus Warren , Sharma Sunil , Qi Jun , Shah Bhavin , Devaraj Santhana G.T. , Leveque Christopher , Portier Bryce P. , Iyer Swaminathan , Bradner James E. , Bhalla Kapil N.
Published: April 2023

Figure Legends for Supplemental Data.
Supplementary Methods and Supplementary Figures S1 through S6 from NSCLC Driven by DDR2 Mutation Is Sensitive to Dasatinib and JQ1 Combination Therapy
Authors: Xu Chunxiao , Buczkowski Kevin A. , Zhang Yanxi , Asahina Hajime , Beauchamp Ellen M. , Terai Hideki , Li Yvonne Y. , Meyerson Matthew , Wong Kwok-kin , Hammerman Peter S.
Published: April 2023

Supplementary Materials and Methods; Figure S1 characterization of mouse model, Figure S2 IHC analysis, Figure S3 DDR2 knock-down studies, Figure S4 cell line drug sensitivity, Figure S5 xenograft individual measurements, Figure S6 JQ1 human cell line sensitivity
Data Supplement from An In Vivo Antilymphatic Screen in Zebrafish Identifies Novel Inhibitors of Mammalian Lymphangiogenesis and Lymphatic-Mediated Metastasis
Authors: Astin Jonathan W. , Jamieson Stephen M.F. , Eng Tiffany C.Y. , Flores Maria V. , Misa June P. , Chien Annie , Crosier Kathryn E. , Crosier Philip S.
Published: April 2023

Video S1. Confocal time-lapse imaging of a lyve1:egfp embryo from 30 hpf to 50:02 hpf (20:02h) treated with 1% DMSO. Time-lapse image z-stacks were collected 10 min apart; movie was made at 7 frames per second.
Supplementary Figure S3 from AMG 595, an Anti-EGFRvIII Antibody–Drug Conjugate, Induces Potent Antitumor Activity against EGFRvIII-Expressing Glioblastoma
Authors: Hamblett Kevin J. , Kozlosky Carl J. , Siu Sophia , Chang Wesley S. , Liu Hua , Foltz Ian N. , Trueblood Esther S. , Meininger David , Arora Taruna , Twomey Brian , Vonderfecht Steven L. , Chen Qing , Hill John S. , Fanslow William C.
Published: April 2023

Supplementary Figure S3. Serum Concentrations of AMG 595 and control conjugate in mice bearing U251vIII xenografts
Supplementary Figure 4 from Vemurafenib Resistance Signature by Proteome Analysis Offers New Strategies and Rational Therapeutic Concepts
Authors: Paulitschke Verena , Berger Walter , Paulitschke Philipp , Hofstätter Elisabeth , Knapp Bernhard , Dingelmaier-Hovorka Ruth , Födinger Dagmar , Jäger Walter , Szekeres Thomas , Meshcheryakova Anastasia , Bileck Andrea , Pirker Christine , Pehamberger Hubert , Gerner Christopher , Kunstfeld Rainer
Published: April 2023

An overview of the applied workflow is depected in Figure S4. All used cell systems and applied techniques are depicted. In addition to that the read out of this study design is visualized,
Legend of Supplementary Figures from Vemurafenib Resistance Signature by Proteome Analysis Offers New Strategies and Rational Therapeutic Concepts
Authors: Paulitschke Verena , Berger Walter , Paulitschke Philipp , Hofstätter Elisabeth , Knapp Bernhard , Dingelmaier-Hovorka Ruth , Födinger Dagmar , Jäger Walter , Szekeres Thomas , Meshcheryakova Anastasia , Bileck Andrea , Pirker Christine , Pehamberger Hubert , Gerner Christopher , Kunstfeld Rainer
Published: April 2023

The legend of the supplemetary figures is given.
Supplementary Methods from Inhibition of Monocarboxylate Transporter-1 (MCT1) by AZD3965 Enhances Radiosensitivity by Reducing Lactate Transport
Authors: Bola Becky M. , Chadwick Amy L. , Michopoulos Filippos , Blount Kathryn G. , Telfer Brian A. , Williams Kaye J. , Smith Paul D. , Critchlow Susan E. , Stratford Ian J.
Published: April 2023

This file contains details of the MTT proliferation assay
Supplementary Information - Metabolites from Inhibition of Monocarboxylate Transporter-1 (MCT1) by AZD3965 Enhances Radiosensitivity by Reducing Lactate Transport
Authors: Bola Becky M. , Chadwick Amy L. , Michopoulos Filippos , Blount Kathryn G. , Telfer Brian A. , Williams Kaye J. , Smith Paul D. , Critchlow Susan E. , Stratford Ian J.
Published: April 2023

This file contains information on the metabolites measured in the metabolomics analysis:
Data Supplement from The CREB-Binding Protein Inhibitor ICG-001 Suppresses Pancreatic Cancer Growth
Authors: Arensman Michael D. , Telesca Donatello , Lay Anna R. , Kershaw Kathleen M. , Wu Nanping , Donahue Timothy R. , Dawson David W.
Published: April 2023

Supplemental Figure 3. Wnt3A effects on ICG-001-mediated inhibition of Wnt reporter and G1 cell cycle arrest.
Data Supplement from The CREB-Binding Protein Inhibitor ICG-001 Suppresses Pancreatic Cancer Growth
Authors: Arensman Michael D. , Telesca Donatello , Lay Anna R. , Kershaw Kathleen M. , Wu Nanping , Donahue Timothy R. , Dawson David W.
Published: April 2023

Supplemental Figure 5. Gene ontology terms enriched in gene expression microarray analysis following β-catenin knockdown.
Data Supplement from The CREB-Binding Protein Inhibitor ICG-001 Suppresses Pancreatic Cancer Growth
Authors: Arensman Michael D. , Telesca Donatello , Lay Anna R. , Kershaw Kathleen M. , Wu Nanping , Donahue Timothy R. , Dawson David W.
Published: April 2023

Supplemental Table 1. PCR primers.
Data Supplement from The CREB-Binding Protein Inhibitor ICG-001 Suppresses Pancreatic Cancer Growth
Authors: Arensman Michael D. , Telesca Donatello , Lay Anna R. , Kershaw Kathleen M. , Wu Nanping , Donahue Timothy R. , Dawson David W.
Published: April 2023

Supplemental Table 3. Top gene expression changes noted in microarray analysis.
Supplementary Table S2 from TAS-116, a Highly Selective Inhibitor of Heat Shock Protein 90α and β, Demonstrates Potent Antitumor Activity and Minimal Ocular Toxicity in Preclinical Models
Authors: Ohkubo Shuichi , Kodama Yasuo , Muraoka Hiromi , Hitotsumachi Hiroko , Yoshimura Chihoko , Kitade Makoto , Hashimoto Akihiro , Ito Kenjiro , Gomori Akira , Takahashi Koichi , Shibata Yoshihiro , Kanoh Akira , Yonekura Kazuhiko
Published: April 2023

Supplementary Table S2: Inhibitory effects of TAS-116 on the metabolic activities catalyzed by various human cytochrome P450 (CYP) enzymes.
Supplementary Materials text from Inhibition of PI3Kβ Signaling with AZD8186 Inhibits Growth of PTEN-Deficient Breast and Prostate Tumors Alone and in Combination with Docetaxel
Authors: Hancox Urs , Cosulich Sabina , Hanson Lyndsey , Trigwell Cath , Lenaghan Carol , Ellston Rebecca , Dry Hannah , Crafter Claire , Barlaam Bernard , Fitzek Martina , Smith Paul D. , Ogilvie Donald , D'Cruz Celina , Castriotta Lillian , Wedge Stephen R. , Ward Lara , Powell Steve , Lawson Mandy , Davies Barry R. , Harrington Elizabeth A. , Foster Emily , Cumberbatch Marie , Green Stephen , Barry Simon T.
Published: April 2023

Supplementary Materials text. Supplementary text to support supplementary data.
Supplementary Table S4 from Synthetic Lethal Screens Identify Vulnerabilities in GPCR Signaling and Cytoskeletal Organization in E-Cadherin–Deficient Cells
Authors: Telford Bryony J. , Chen Augustine , Beetham Henry , Frick James , Brew Tom P. , Gould Cathryn M. , Single Andrew , Godwin Tanis , Simpson Kaylene J. , Guilford Parry
Published: April 2023

Supplementary Table S4. Synthetic lethal siRNAs that are associated with the drug classes identified as being CDH1 synthetic lethal in the known drug screen.
Supplemental Materials and Methods and Supplemental Figure Legends from Inhibition of mTORC2 Induces Cell-Cycle Arrest and Enhances the Cytotoxicity of Doxorubicin by Suppressing MDR1 Expression in HCC Cells
Authors: Chen Bryan Wei , Chen Wei , Liang Hui , Liu Hao , Liang Chao , Zhi Xiao , Hu Li-qiang , Yu Xia-Zhen , Wei Tao , Ma Tao , Xue Fei , Zheng Lei , Zhao Bin , Feng Xin-Hua , Bai Xue-li , Liang Ting-bo
Published: April 2023

Supplemental Materials and Methods and Supplemental Figure Legends
Supplementary Table S2 from Synthetic Lethal Screens Identify Vulnerabilities in GPCR Signaling and Cytoskeletal Organization in E-Cadherin–Deficient Cells
Authors: Telford Bryony J. , Chen Augustine , Beetham Henry , Frick James , Brew Tom P. , Gould Cathryn M. , Single Andrew , Godwin Tanis , Simpson Kaylene J. , Guilford Parry
Published: April 2023

Supplementary Table S2. DAVID gene ontology analysis.
Figure S2 from Radiotherapy Followed by Aurora Kinase Inhibition Targets Tumor-Propagating Cells in Human Glioblastoma
Authors: Li Nan , Maly Dustin J. , Chanthery Yvan H. , Sirkis Daniel W. , Nakamura Jean L. , Berger Mitchel S. , James C. David , Shokat Kevan M. , Weiss William A. , Persson Anders I.
Published: April 2023

Figure S2. Expression of potential targets of VX680 in human GBM cultures.
Supplementary Figure S1 from Synthetic Lethal Screens Identify Vulnerabilities in GPCR Signaling and Cytoskeletal Organization in E-Cadherin–Deficient Cells
Authors: Telford Bryony J. , Chen Augustine , Beetham Henry , Frick James , Brew Tom P. , Gould Cathryn M. , Single Andrew , Godwin Tanis , Simpson Kaylene J. , Guilford Parry
Published: April 2023

Supplementary Figure S1. Cell viability normalized to mock for a range of siRNAs tested as potential synthetic lethal controls.
Supplemental figure legends from Inhibition of ABCB1 Overcomes Cancer Stem Cell–like Properties and Acquired Resistance to MET Inhibitors in Non–Small Cell Lung Cancer
Authors: Sugano Teppei , Seike Masahiro , Noro Rintaro , Soeno Chie , Chiba Mika , Zou Fenfei , Nakamichi Shinji , Nishijima Nobuhiko , Matsumoto Masaru , Miyanaga Akihiko , Kubota Kaoru , Gemma Akihiko
Published: April 2023

Supplemental figure legends 1-4
Supplemental Figure 5 from CD24+ Ovarian Cancer Cells Are Enriched for Cancer-Initiating Cells and Dependent on JAK2 Signaling for Growth and Metastasis
Authors: Burgos-Ojeda Daniela , Wu Rong , McLean Karen , Chen Yu-Chih , Talpaz Moshe , Yoon Euisik , Cho Kathleen R. , Buckanovich Ronald J.
Published: April 2023

Supplemental Figure 5. FACS isolation strategy and purity of sort
Supplemental Figure 4 from CD24+ Ovarian Cancer Cells Are Enriched for Cancer-Initiating Cells and Dependent on JAK2 Signaling for Growth and Metastasis
Authors: Burgos-Ojeda Daniela , Wu Rong , McLean Karen , Chen Yu-Chih , Talpaz Moshe , Yoon Euisik , Cho Kathleen R. , Buckanovich Ronald J.
Published: April 2023

Supplemental Figure 4. Confirmation of JAK2 depletion by siRNA
Supplementary Figure S5 from Evaluation of Novel Imidazotetrazine Analogues Designed to Overcome Temozolomide Resistance and Glioblastoma Regrowth
Authors: Ramirez Yulian P. , Mladek Ann C. , Phillips Roger M. , Gynther Mikko , Rautio Jarkko , Ross Alonzo H. , Wheelhouse Richard T. , Sakaria Jann N.
Published: April 2023

Supplementary Figure S5. DNA damage signaling activated by low concentrations of DP68. U251 and T98G cells were exposed to DP68 for 24 hrs and whole cell and nuclear extracts were processed for Western blotting. Representative blots from three independent experiments are shown.
Supplementary Figures S1-3 and Table S1 from 23814, an Inhibitory Antibody of Ligand-Mediated Notch1 Activation, Modulates Angiogenesis and Inhibits Tumor Growth without Gastrointestinal Toxicity
Authors: Proia Theresa , Jiang Feng , Bell Alisa , Nicoletti Richard , Kong Lingxin , Kreuter Kelly , Poling Laura , Winston William M. , Flaherty Meghan , Weiler Solly , Perino Samantha , O'Hagan Ronan , Lin Jie , Gyuris Jeno , Okamura Heidi
Published: April 2023

Supplementary Figures S1-3 and Table S1. Supplementary Figure S1: Histopathology and 23814 Serum Concentration at end of toxicity study Supplementary Figure S2: 23814 Treatment Increases Vasculature Even in Tumors with Limited Response Supplementary Figure S3: 23814/Tivozanib Combination Treatment Increases Tumor Necrosis Supplementary Table S1: Clinical Pathology Analysis
Supplementary Figure Legends from 23814, an Inhibitory Antibody of Ligand-Mediated Notch1 Activation, Modulates Angiogenesis and Inhibits Tumor Growth without Gastrointestinal Toxicity
Authors: Proia Theresa , Jiang Feng , Bell Alisa , Nicoletti Richard , Kong Lingxin , Kreuter Kelly , Poling Laura , Winston William M. , Flaherty Meghan , Weiler Solly , Perino Samantha , O'Hagan Ronan , Lin Jie , Gyuris Jeno , Okamura Heidi
Published: April 2023

Supplementary Figure Legends. Figure legends for supplementary figures S1, S2, S3 and table S1.
Supplimentary Figure S2: Kaplan-Meier curves estimation of DFS and OS for patients with high or low methylation levels stratified by tumor stage or the receipt of concurrent chemotherapy from Genome-Wide Identification of a Methylation Gene Panel as a Prognostic Biomarker in Nasopharyngeal Carcinoma
Authors: Jiang Wei , Liu Na , Chen Xiao-Zhong , Sun Ying , Li Bin , Ren Xian-Yue , Qin Wei-Feng , Jiang Ning , Xu Ya-Fei , Li Ying-Qin , Ren Jian , Cho William CS , Yun Jing-Ping , Zeng Jing , Liu Li-Zhi , Li Li , Guo Ying , Mai Hai-Qiang , Zeng Mu-Sheng , Kang Tie-Bang , Jia Wei-Hua , Shao Jian-Yong , Ma Jun
Published: April 2023

Kaplan-Meier curves estimation of disease-free survival (DFS) and overall survival (OS) for patients with high or low methylation levels stratified by tumor stage or the receipt of concurrent chemotherapy.
Supplementary Table S3 from Target Identification in Small Cell Lung Cancer via Integrated Phenotypic Screening and Activity-Based Protein Profiling
Authors: Li Jiannong , Fang Bin , Kinose Fumi , Bai Yun , Kim Jae-Young , Chen Yian A. , Rix Uwe , Koomen John M. , Haura Eric B.
Published: April 2023

Hits of K14 and B13 identified by ATP probe-based drug profiling in SW210.5 cells
Supplemental Methods and Legends from Target Identification in Small Cell Lung Cancer via Integrated Phenotypic Screening and Activity-Based Protein Profiling
Authors: Li Jiannong , Fang Bin , Kinose Fumi , Bai Yun , Kim Jae-Young , Chen Yian A. , Rix Uwe , Koomen John M. , Haura Eric B.
Published: April 2023

Supplemental methods and legends for supplemental figures S1 to S3 and supplemental tables S1 to S3
Supplementary Tables S1-S2 and Supplementary Figures S1-S5 from The DNA Repair Inhibitor DT01 as a Novel Therapeutic Strategy for Chemosensitization of Colorectal Liver Metastasis
Authors: Herath Nirmitha I. , Devun Flavien , Lienafa Marie-Christine , Herbette Aurélie , Denys Alban , Sun Jian-Sheng , Dutreix Marie
Published: April 2023

Table S1: Treatment group allocation of mice post intrahepatic grafting; Figure S1: DT01 in combination with single agent chemotherapy; Figure S2: Proportion of apoptotic nuclei in HES sections; Figure S3: Average body weight (g) of mice during treatment; Figure S4: Liver function assessment; Figure S5: Average body and liver weights (g) of mice during treatment with escalating doses of DT01 in association with OXA or 5-FU; Table S2: Summary of main findings
supplementary figures from A Novel Small Molecule Activator of Nuclear Receptor SHP Inhibits HCC Cell Migration via Suppressing Ccl2
Authors: Yang Zhihong , Koehler Angela N. , Wang Li
Published: April 2023

Figure S1: Images for supplementary information on SMM screens; Figure S2: The detail information of compound DSHN; Figure S3: MTT assay in MHCC97H, Huh7 and Hepa1 cells treated with indicated concentration of compound #29 (DSHN) for 72 hours; Figure S4: A-B: Mammalian two hybrid assay; Figure S5: A. Semi-quantitative PCR analysis of mShp mRNA in SHP transgenic mice (stg) liver; Figure S6: The DNA copy number of SHP gene were analyzed from The Cancer Genome Atlas; Figure S7: A. Survival proportions for lung cancer. B. Survival proportions for ovarian cancer stage 4. C. Quantitative RTPCR profiling of the nuclear receptor superfamily in thirty pairs of human lung tumor and corresponding normal epithelium.
Supplementary Figure 4 from Combining Onartuzumab with Erlotinib Inhibits Growth of Non–Small Cell Lung Cancer with Activating EGFR Mutations and HGF Overexpression
Authors: Sano Yuji , Hashimoto Eri , Nakatani Noriaki , Abe Masaichi , Satoh Yasuko , Sakata Kiyoaki , Fujii Toshihiko , Fujimoto-Ouchi Kaori , Sugimoto Masamichi , Nagahashi Shigehisa , Aoki Masahiro , Motegi Hiroshi , Sasaki Eiichi , Yatabe Yasushi
Published: April 2023

Supplementary Figure 4. Representative images of MET-IHC scoring 0, +1, +2, +3.
Supplementary Figure 2 from Combining Onartuzumab with Erlotinib Inhibits Growth of Non–Small Cell Lung Cancer with Activating EGFR Mutations and HGF Overexpression
Authors: Sano Yuji , Hashimoto Eri , Nakatani Noriaki , Abe Masaichi , Satoh Yasuko , Sakata Kiyoaki , Fujii Toshihiko , Fujimoto-Ouchi Kaori , Sugimoto Masamichi , Nagahashi Shigehisa , Aoki Masahiro , Motegi Hiroshi , Sasaki Eiichi , Yatabe Yasushi
Published: April 2023

Supplementary Figure 2. Characteristics of HGF-overexpressing clones in PC-9 and HCC827 cells.
Supplementary Table S2 from Glycogen Synthase Kinase 3β Sustains Invasion of Glioblastoma via the Focal Adhesion Kinase, Rac1, and c-Jun N-Terminal Kinase-Mediated Pathway
Authors: Chikano Yuri , Domoto Takahiro , Furuta Takuya , Sabit Hemragul , Kitano-Tamura Ayako , Pyko Ilya V. , Takino Takahisa , Sai Yoshimichi , Hayashi Yutaka , Sato Hiroshi , Miyamoto Ken-ichi , Nakada Mitsutoshi , Minamoto Toshinari
Published: April 2023

Sequence of the primers for quantitative RT-PCR.
Supplementary Figure S3 from Glycogen Synthase Kinase 3β Sustains Invasion of Glioblastoma via the Focal Adhesion Kinase, Rac1, and c-Jun N-Terminal Kinase-Mediated Pathway
Authors: Chikano Yuri , Domoto Takahiro , Furuta Takuya , Sabit Hemragul , Kitano-Tamura Ayako , Pyko Ilya V. , Takino Takahisa , Sai Yoshimichi , Hayashi Yutaka , Sato Hiroshi , Miyamoto Ken-ichi , Nakada Mitsutoshi , Minamoto Toshinari
Published: April 2023

Effect of GSK3beta inhibition on expression of ECT2, Vav3 and integrins mRNA in glioblastoma cells.
Supplementary Table 1 from Lurbinectedin Specifically Triggers the Degradation of Phosphorylated RNA Polymerase II and the Formation of DNA Breaks in Cancer Cells
Authors: Santamaría Nuñez Gema , Robles Carlos Mario Genes , Giraudon Christophe , Martínez-Leal Juan Fernando , Compe Emmanuel , Coin Frédéric , Aviles Pablo , Galmarini Carlos María , Egly Jean-Marc
Published: April 2023

Growth inhibitory activity of lurbinectedin on different cancer cell lines.
Supplementary Figure 6 from Lurbinectedin Specifically Triggers the Degradation of Phosphorylated RNA Polymerase II and the Formation of DNA Breaks in Cancer Cells
Authors: Santamaría Nuñez Gema , Robles Carlos Mario Genes , Giraudon Christophe , Martínez-Leal Juan Fernando , Compe Emmanuel , Coin Frédéric , Aviles Pablo , Galmarini Carlos María , Egly Jean-Marc
Published: April 2023

Figure S6. Lurbinectedin induces RNA pol II degradation and DNA breaks formation in mice A549 xenograft models. Mice tumors were biopsied at 0, 7, 14, 21 and 28 days after lurbinectedin treatment and the degradation of Pol II and the presence of DNA breaks were evaluated by using RPb1 and Î³-H2AX antibodies, respectively. Î²-Tubulin (Tub) antibody has been used as a control.
Supplementary Figure Legends from Glycogen Synthase Kinase 3β Sustains Invasion of Glioblastoma via the Focal Adhesion Kinase, Rac1, and c-Jun N-Terminal Kinase-Mediated Pathway
Authors: Chikano Yuri , Domoto Takahiro , Furuta Takuya , Sabit Hemragul , Kitano-Tamura Ayako , Pyko Ilya V. , Takino Takahisa , Sai Yoshimichi , Hayashi Yutaka , Sato Hiroshi , Miyamoto Ken-ichi , Nakada Mitsutoshi , Minamoto Toshinari
Published: April 2023

Legends to Supplementary Figure S1 to S6
Supplementary Figure 4 from Lurbinectedin Specifically Triggers the Degradation of Phosphorylated RNA Polymerase II and the Formation of DNA Breaks in Cancer Cells
Authors: Santamaría Nuñez Gema , Robles Carlos Mario Genes , Giraudon Christophe , Martínez-Leal Juan Fernando , Compe Emmanuel , Coin Frédéric , Aviles Pablo , Galmarini Carlos María , Egly Jean-Marc
Published: April 2023

Figure S4. Proposed mechanism of action of lurbinectedin Upon administration to cancer cells, (I) lurbinectedin targets GC rich regions; (II) Pol II starts the elongation phase of transcription of activated genes after being sequentially phosphorylated by CDK7 (TFIIH) and CDK9 (pTEFb), (III) Pol II might be blocked by lurbinectedin and recruits DNA repair factors; (IV and V) the ubiquitinated Pol II is being degraded by ubiquitin proteasome machinery; (VI) the elongating Pol II stalled in front of the lesion induces DNA breaks that could have been originated from the activity of endonucleases such as XPF and/or Topo IIâ^�.
Figure S5 from Neuregulin 1 Allosterically Enhances the Antitumor Effects of the Noncompeting Anti-HER3 Antibody 9F7-F11 by Increasing Its Binding to HER3
Authors: Le Clorennec Christophe , Bazin Hervé , Dubreuil Olivier , Larbouret Christel , Ogier Charline , Lazrek Yassamine , Garambois Véronique , Poul Marie-Alix , Mondon Philippe , Barret Jean-Marc , Mathis Gérard , Prost Jean-François , Pèlegrin André , Chardès Thierry
Published: April 2023

Supplemental Fig.S5. Relative NRG1a, NRG1b and EGF mRNA expression in the cancer cell lines HCC-1806, BxPC3, A549 and HPAC. Quantification data were normalized to the amplification data for the reference gene HPRT.
Figure S2 from Neuregulin 1 Allosterically Enhances the Antitumor Effects of the Noncompeting Anti-HER3 Antibody 9F7-F11 by Increasing Its Binding to HER3
Authors: Le Clorennec Christophe , Bazin Hervé , Dubreuil Olivier , Larbouret Christel , Ogier Charline , Lazrek Yassamine , Garambois Véronique , Poul Marie-Alix , Mondon Philippe , Barret Jean-Marc , Mathis Gérard , Prost Jean-François , Pèlegrin André , Chardès Thierry
Published: April 2023

Supplemental Fig.S2. 9F7-F11 is a positive-allosteric modulator of NRG1 binding to HER3. NRG1 does not compete with 9F7-F11, differently from what observed with H4B-121 and MAB3481, and NRG1 binding to HER3 increases in the presence of 9F7-F11. SNAP-Tag Lumi4TM-Tb HER3-expressing HEK cells were co-incubated with various concentrations of unlabeled antibodies and 20nM d2-conjugated NRG1. After 5h30 incubation, the time-resolved fluorescence (665 nm/620 nm emission delta ratio) of NRG1-d2 binding to HER3 was measured on a Pherastar reader and normalized to 100% binding (antibody-d2 conjugates without NRG1, or NRG1-d2 conjugates without antibodies). Data were plotted using the GraphPad Prism software.
Supplementary Table 1 from Sorafenib Suppresses JNK-Dependent Apoptosis through Inhibition of ZAK
Authors: Vin Harina , Ching Grace , Ojeda Sandra S. , Adelmann Charles H. , Chitsazzadeh Vida , Dwyer David W. , Ma Haiching , Ehrenreiter Karin , Baccarini Manuela , Ruggieri Rosamaria , Curry Jonathan L. , Ciurea Ana M. , Duvic Madeleine , Busaidy Naifa L. , Tannir Nizar M. , Tsai Kenneth Y.
Published: April 2023

PDF - 69KB, In-vitro kinase assays were performed against sorafenib with a staurosporine positive control across a concentration range of 0.5 nM to 10 μM). Blank values are those for which no significant inhibition occurred over the entire concentration range.
Supplementary Figure 1 from Sorafenib Suppresses JNK-Dependent Apoptosis through Inhibition of ZAK
Authors: Vin Harina , Ching Grace , Ojeda Sandra S. , Adelmann Charles H. , Chitsazzadeh Vida , Dwyer David W. , Ma Haiching , Ehrenreiter Karin , Baccarini Manuela , Ruggieri Rosamaria , Curry Jonathan L. , Ciurea Ana M. , Duvic Madeleine , Busaidy Naifa L. , Tannir Nizar M. , Tsai Kenneth Y.
Published: April 2023

PDF - 1060KB, Sorafenib suppresses JNK-dependent apoptosis as assessed by cleaved caspase 3.
Supplementary Figure 5 from TRX-E-002-1 Induces c-Jun–Dependent Apoptosis in Ovarian Cancer Stem Cells and Prevents Recurrence In Vivo
Authors: Alvero Ayesha B. , Heaton Andrew , Lima Eydis , Pitruzzello Mary , Sumi Natalia , Yang-Hartwich Yang , Cardenas Carlos , Steinmacher Sahra , Silasi Dan-Arin , Brown David , Mor Gil
Published: April 2023

TRX-E-002-1 decreases tumor burden and activates c-jun in vivo. Mice were treated i.p. daily with 50 mg/kg or 100 mg/kg TRX-E-002-1 . (A) quantification of total i.p. tumor burden at end of study; (B) western blot analysis for p-c-Jun and total c-Jun in residual tumors from C, control mice or T, mice treated with TRX-E-002-1 100 mg/kg. Representative western blot from two controls and two TRX-E-002-1- treated mice; (C) quantification total i.p. tumor burden at end of maintenance treatment
Supplementary Figure 4 from TRX-E-002-1 Induces c-Jun–Dependent Apoptosis in Ovarian Cancer Stem Cells and Prevents Recurrence In Vivo
Authors: Alvero Ayesha B. , Heaton Andrew , Lima Eydis , Pitruzzello Mary , Sumi Natalia , Yang-Hartwich Yang , Cardenas Carlos , Steinmacher Sahra , Silasi Dan-Arin , Brown David , Mor Gil
Published: April 2023

TRX-E-002-1 given daily at 100 mg/kg is tolerated. Mice were treated i.p. daily with 50 mg/kg or 100 mg/kg TRX-E-002-1 . (A) change in animal weight by the end of study, * p = 0.0147; (B) WBC count, p > 0.05.
SupMovie1a from TRX-E-002-1 Induces c-Jun–Dependent Apoptosis in Ovarian Cancer Stem Cells and Prevents Recurrence In Vivo
Authors: Alvero Ayesha B. , Heaton Andrew , Lima Eydis , Pitruzzello Mary , Sumi Natalia , Yang-Hartwich Yang , Cardenas Carlos , Steinmacher Sahra , Silasi Dan-Arin , Brown David , Mor Gil
Published: April 2023

Cells treated with TRX-E-002-1
Supplementary Tables S1-S4 from Pathway-Enriched Gene Signature Associated with 53BP1 Response to PARP Inhibition in Triple-Negative Breast Cancer
Authors: Hassan Saima , Esch Amanda , Liby Tiera , Gray Joe W. , Heiser Laura M.
Published: April 2023

Supplementary Table S1. Molecular features of breast cancer cell line panel with doubling time, receptor status, gene cluster status, breast cancer subtypes, and mutation status; Supplementary Table S2: IC50 values for each PARP inhibitor with SD for replicate experiments; Supplementary Table S3: Fold-change differences in IC50 values between talazoparib versus olaparib, and olaparib versus veliparib; Supplementary Table S4. Mutated genes in triple-negative breast cancer patients with druggable potential
Supplementary Figure S3 from Targeting BRG1 Chromatin Remodeler via Its Bromodomain for Enhanced Tumor Cell Radiosensitivity In Vitro and In Vivo
Authors: Kwon Su-Jung , Lee Seul-Ki , Na Juri , Lee Shin-Ai , Lee Han-Sae , Park Ji-Hye , Chung June-Key , Youn Hyewon , Kwon Jongbum
Published: April 2023

Supplementary Figure S3. BRG1-BRD inhibits ÃŽÂ³-H2AX formation and DSB repair in irradiated MDA-MB-231 cells and this activity is enhanced by dimerization.
Supplementary Figures S1-S3 from Pathway-Enriched Gene Signature Associated with 53BP1 Response to PARP Inhibition in Triple-Negative Breast Cancer
Authors: Hassan Saima , Esch Amanda , Liby Tiera , Gray Joe W. , Heiser Laura M.
Published: April 2023

Supplementary Figure S1. Pipeline of steps taken to identify pathway enriched genes; Supplementary Figure S2. Representative IC50 dose-response curves for veliparib, olaparib, talazoparib, and carboplatin for A) HCC1143, B) MDAMB231, C) HCC1806, D) HCC1395, and E) MDAMB436; Supplementary Figure S3. 53BP1 expression.
Supplemental figures 1-2 from Dual and Specific Inhibition of NAMPT and PAK4 By KPT-9274 Decreases Kidney Cancer Growth
Authors: Abu Aboud Omran , Chen Ching-Hsien , Senapedis William , Baloglu Erkan , Argueta Christian , Weiss Robert H.
Published: April 2023

Supplemental figure 1. Lack of toxicity of KPT-9274 at 24 hours; Supplemental figure 2. Cell cycle analysis.
Supplementary Figure 2 from Response to MLN8237 in Pancreatic Cancer Is Not Dependent on RalA Phosphorylation
Authors: Neel Nicole F. , Stratford Jeran K. , Shinde Vaishali , Ecsedy Jeffrey A. , Martin Timothy D. , Der Channing J. , Yeh Jen Jen
Published: April 2023

PDF - 609K, pRalA validation.
Supplementary Figure S3 from Activation of the Constitutive Androstane Receptor Increases the Therapeutic Index of CHOP in Lymphoma Treatment
Authors: Hedrich William D. , Xiao Jingwei , Heyward Scott , Zhang Yao , Zhang Junran , Baer Maria R. , Hassan Hazem E. , Wang Hongbing
Published: April 2023

Effects of CAR activation on the expression of genes responsible for CHOP disposition in H9c2 cells and rat liver.
Supplementary Table 4 from A Novel Compound, NK150460, Exhibits Selective Antitumor Activity against Breast Cancer Cell Lines through Activation of Aryl Hydrocarbon Receptor
Authors: Fukasawa Kazuteru , Kagaya Shigehide , Maruyama Sakiko , Kuroiwa Shunsuke , Masuda Kuniko , Kameyama Yoshio , Satoh Yoshitaka , Akatsu Yuichi , Tomura Arihiro , Nishikawa Kiyohiro , Horie Shigeo , Ichikawa Yuh-ichiro
Published: April 2023

Supplementary Table 4. Expression of AhR mRNA in various breast cancer cell lines.
Supplementary Figure S1 from Activation of the Constitutive Androstane Receptor Increases the Therapeutic Index of CHOP in Lymphoma Treatment
Authors: Hedrich William D. , Xiao Jingwei , Heyward Scott , Zhang Yao , Zhang Junran , Baer Maria R. , Hassan Hazem E. , Wang Hongbing
Published: April 2023

Activation of CAR improves the anticancer activity of the FC regimen in HPH/HL-60 co-culture.
Supplementary Figure 5 from A Novel Compound, NK150460, Exhibits Selective Antitumor Activity against Breast Cancer Cell Lines through Activation of Aryl Hydrocarbon Receptor
Authors: Fukasawa Kazuteru , Kagaya Shigehide , Maruyama Sakiko , Kuroiwa Shunsuke , Masuda Kuniko , Kameyama Yoshio , Satoh Yoshitaka , Akatsu Yuichi , Tomura Arihiro , Nishikawa Kiyohiro , Horie Shigeo , Ichikawa Yuh-ichiro
Published: April 2023

Supplementary Figure 5. Growth-inhibitory activity of NK150460 in CYP1A1-overexpressing HEK293 cells was not affected by AhR.
Supplementary Figure 4 from Dual Targeting of Bromodomain and Extraterminal Domain Proteins, and WNT or MAPK Signaling, Inhibits c-MYC Expression and Proliferation of Colorectal Cancer Cells
Authors: Tögel Lars , Nightingale Rebecca , Chueh Anderly C. , Jayachandran Aparna , Tran Hoanh , Phesse Toby , Wu Rui , Sieber Oliver M. , Arango Diego , Dhillon Amardeep S. , Dawson Mark A. , Diez-Dacal Beatriz , Gahman Timothy C. , Filippakopoulos Panagis , Shiau Andrew K. , Mariadason John M.
Published: April 2023

Basal MYC (A) mRNA and (B) protein expression in 20 CRC cell lines. Correlation of c-MYC (C) mRNA and (D) protein with JQ1 response.
Supplementary Figure 2 from A Novel Compound, NK150460, Exhibits Selective Antitumor Activity against Breast Cancer Cell Lines through Activation of Aryl Hydrocarbon Receptor
Authors: Fukasawa Kazuteru , Kagaya Shigehide , Maruyama Sakiko , Kuroiwa Shunsuke , Masuda Kuniko , Kameyama Yoshio , Satoh Yoshitaka , Akatsu Yuichi , Tomura Arihiro , Nishikawa Kiyohiro , Horie Shigeo , Ichikawa Yuh-ichiro
Published: April 2023

Supplementary Figure 2. Knock down effect of each siRNA used in Figure 2(C).
Supplementary Tables S1-S9 from Characterization of LY3023414, a Novel PI3K/mTOR Dual Inhibitor Eliciting Transient Target Modulation to Impede Tumor Growth
Authors: Smith Michele C. , Mader Mary M. , Cook James A. , Iversen Philip , Ajamie Rose , Perkins Everett , Bloem Laura , Yip Yvonne Y. , Barda David A. , Waid Philip P. , Zeckner Douglas J. , Young Debra A. , Sanchez-Felix Manuel , Donoho Gregory P. , Wacheck Volker
Published: April 2023

PDF - 182 KB, Table S1. Kinase selectivity profile for LY3023414 in Cerep and Life Technologies assays based on a 3-point concentration response curve; Table S2. In vitro inhibitory activity of LY3023414 against kinases in a PC3 cell lysate measured in the KiNativ assay based on a 3-point concentration response curve; Table S3. In vitro cell-based target inhibition in SKOV3, A2780, and AsPC-1; Table S4. Summary of pathway-relevant genetic alterations in cancer cell line panel and in selected patient-derived xenograft tumor models tested; Table S5. Activated caspase-3/7 levels in cell lines treated with 2.5 μM LY3023414 for 48 hours; Table S6. In vitro combination studies with LY3023414 and standard of care agents in various cancer cell lines; Table S7. Time course of in vivo target inhibition in U87 MG xenograft tumors after oral administration of 15 and 30 mg/kg LY3023414; Table S8. Summary of LY3023414 monotherapy efficacy in patient-derived xenograft tumor models; Table S9. Summary of LY3023414 combination efficacy in patient-derived xenograft squamous non-small cell lung cancer (NSCLC) tumor models.
Supplementary Figure Legends from Characterization of LY3023414, a Novel PI3K/mTOR Dual Inhibitor Eliciting Transient Target Modulation to Impede Tumor Growth
Authors: Smith Michele C. , Mader Mary M. , Cook James A. , Iversen Philip , Ajamie Rose , Perkins Everett , Bloem Laura , Yip Yvonne Y. , Barda David A. , Waid Philip P. , Zeckner Douglas J. , Young Debra A. , Sanchez-Felix Manuel , Donoho Gregory P. , Wacheck Volker
Published: April 2023

PDF - 101 KB
Supplementary Video S2 from A Murine Model for Quantitative, Real-Time Evaluation of Convection-Enhanced Delivery (RT-CED) Using an 18[F]-Positron Emitting, Fluorescent Derivative of Dasatinib
Authors: Wang Melinda , Kommidi Harikrishna , Tosi Umberto , Guo Hua , Zhou Zhiping , Schweitzer Melanie E. , Wu Linda Y. , Singh Ranjodh , Hou Shengqi , Law Benedict , Ting Richard , Souweidane Mark M.
Published: April 2023

Supporting Video S2. Sagittal PET(red)/ MR(grey) projection showing dynamic, CED delivery of [18F]-1 (Video of Fig.3Bi)
Figure S3 from A Novel Inhibitor of Topoisomerase I Is Selectively Toxic for a Subset of Non–Small Cell Lung Cancer Cell Lines
Authors: Zubovych Iryna O. , Sethi Anirudh , Kulkarni Aditya , Tagal Vural , Roth Michael G.
Published: April 2023

Figure S3. SW044248 induces a DNA damage response in sensitive, but not resistant cell lines.
Figure S2 from A Novel Inhibitor of Topoisomerase I Is Selectively Toxic for a Subset of Non–Small Cell Lung Cancer Cell Lines
Authors: Zubovych Iryna O. , Sethi Anirudh , Kulkarni Aditya , Tagal Vural , Roth Michael G.
Published: April 2023

Figure S2. SW044248 rapidly inhibits RNA, DNA, and protein synthesis in H292 cells but not in HCC44 cells and SW202742 does not inhibit macromolecular synthesis in HCC4-17 cells.
Supplementary Video 3 from A Murine Model for Quantitative, Real-Time Evaluation of Convection-Enhanced Delivery (RT-CED) Using an 18[F]-Positron Emitting, Fluorescent Derivative of Dasatinib
Authors: Wang Melinda , Kommidi Harikrishna , Tosi Umberto , Guo Hua , Zhou Zhiping , Schweitzer Melanie E. , Wu Linda Y. , Singh Ranjodh , Hou Shengqi , Law Benedict , Ting Richard , Souweidane Mark M.
Published: April 2023

Supporting Video S3. Horizontal PET(red)/CT(blue) projection showing dynamic, CED delivery of [18F]-1. PET is overexposed to emphasize gastrointestinal clearance. Exposure does not affect SUV quantitation (Video of Fig.4Aii and iii)
Figure S1 from A Novel Inhibitor of Topoisomerase I Is Selectively Toxic for a Subset of Non–Small Cell Lung Cancer Cell Lines
Authors: Zubovych Iryna O. , Sethi Anirudh , Kulkarni Aditya , Tagal Vural , Roth Michael G.
Published: April 2023

Figure S1. SW044248 shows differential activation of apoptosis in multiple cell lines.